Omega-3 carboxylic acids - AstraZeneca

Drug Profile

Omega-3 carboxylic acids - AstraZeneca

Alternative Names: AZD 0585; D-5884; DHA/EPA - AstraZeneca; Docosahexaenoic acid/eicosapentaenoic acid - AstraZeneca; Eicosapentaenoic acid/docosahexaenoic acid - AstraZeneca; EPA/DHA - AstraZeneca; Epanova; Omefas; Purepa

Latest Information Update: 27 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Tillotts Pharma
  • Developer AstraZeneca; Cleveland Clinic; Tillotts Pharma
  • Class Antihyperlipidaemics; Carboxylic acids; Docosahexaenoic acids; Eicosanoids; Omega 3 fatty acids; Omega-6 fatty acids
  • Mechanism of Action Lipid modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Registered Hypertriglyceridaemia
  • Phase II Non-alcoholic fatty liver disease
  • Research Cardiovascular disorders
  • Discontinued Crohn's disease

Most Recent Events

  • 27 Jul 2017 Omega-3 carboxylic acids is still Registered (not yet launched) for Hypertriglyceridaemia in USA (AstraZeneca pipeline, July 2017)
  • 06 May 2017 Efficacy data from a phase II trial in Hypertriglyceridaemia presented at the Digestive Disease Week 2017 (DDW-2017)
  • 11 Mar 2017 AstraZeneca completes a phase III trial in Hypertriglyceridaemia in Japan (PO) (NCT02463071)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top